Roche Advances in the Obesity Drug Race with Bold Acquisition
+0.04%current return
"Roche, the Swiss pharma company, has agreed to buy 89 bio for over an 80 percent premium. We're seeing shares of 89 bio up over 83 percent in the pre-market. Now, this is Roche's third acquisition to try to position itself better in the obesity drug race. ... It's another landmark deal for Roche, who's trying to compete and catch up with Novo Nordisk and Eli Lilly in the obesity drug space."
— Nathan Hager & Valerie Teitel
The segment highlights Roche's strategic move to acquire 89 bio at a significant premium and contingent payment structure, which is intended to bolster its competitiveness in the obesity drug market against peers like Novo Nordisk and Eli Lilly.
Company CommentaryBullish High ConvictionScore: 7.8
Company Opinion •Stock Movers • about 1 month ago